Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that hormone therapy is essential for treating gender dysphoria, with specific drugs and monitoring protocols recommended for safety and effectiveness.

The survey helps identify menstrual irregularities and excess male hormones, aiming to detect conditions like Polycystic Ovary Syndrome.

PCOS and eating disorders are linked by hormonal imbalances, needing personalized treatment.

Hormone therapy increases facial and body hair in transgender men, while hair removal improves well-being in transgender women, but cost is a barrier as insurance often doesn't cover it. Dermatologists can use various treatments for these hair issues.

The document likely discusses how to tell the difference between excessive hair growth and the development of male characteristics in women.

Testosterone treatment in trans men increases body and facial hair and may lead to hair loss over time, but severe skin issues are rare.

Male pattern baldness is an unintended side effect of the body's use of androgens for muscle growth, especially in those genetically prone to it.

Cetuximab can cause unusual hair growth and hair loss.

Dermatologists are essential in helping transgender and gender diverse patients with skin and hair issues related to gender affirmation and hormone therapy.

Hormonal therapy changes skin and hair in transgender patients, who need better researched dermatologic care.

Testosterone therapy for transmasculine individuals is generally safe with medical supervision, improves mental health, and has mixed effects on physical health.

Topical minoxidil helps transgender individuals assigned female at birth grow more facial hair.

A small molecule can strengthen fine hair, making it more resistant and natural-feeling.

Testosterone therapy in transgender men has both desired effects like increased muscle mass and potential health risks such as higher cardiovascular risk.

The document concludes that non-operative treatment for gender dysphoria is safe and effective, and hormone therapy does not increase cancer risk.

Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.

Mice are useful for researching human hair loss and testing treatments, despite some differences between species.

Most cases of excessive hair growth in women are caused by polycystic ovarian syndrome and are linked to higher free testosterone levels.

Metformin helps with menstrual cycles and insulin levels in PCOS but is less effective for hair growth, diabetes prevention, and weight loss, and may improve fertility and reduce diabetes risk.

Antiandrogens like flutamide are effective in treating conditions like prostate cancer and hair loss, but there's a need for more potent versions. Understanding their structure can help develop better treatments.

Men prefer less invasive cosmetic procedures and need different treatment approaches than women.

Power-enhancing drugs can cause mood swings, aggression, anxiety, and physical side effects, questioning their overall benefits.

A certain genetic variation is linked to a higher risk of polycystic ovarian syndrome.

Some antiandrogens may lower testosterone better than others, but it's unclear which is best for feminization in transgender women; more research is needed.

More men are getting cosmetic surgery, with Botox and hair removal being popular, but these procedures have risks.

DHEA may help with sexual function when used intravaginally by menopausal women but is similar to hormone therapy in other aspects and might cause more side effects like acne and hair loss.

Women with PCOS face many health risks, but exercise, a healthy diet, and weight management can help.

Ovarian Leydig cell tumors are hard to diagnose with just advanced imaging; expert ultrasound and clinical evaluation are essential.

The document concludes that proper diagnosis and tailored long-term treatment can effectively manage androgenic disorders in women, improving patient care outcomes.

Gender-affirming hormone therapy improves physical performance in trans men to the level of cisgender men, while in trans women, it increases fat mass and decreases muscle mass, with no advantage in physical performance after 2 years.